OBJECTIVES To compare outcomes from accelerated alteplase (recombinant tissue plasminogen activator, t-PA) and streptokinase use in acute myocardial infarction. METHODS Review of available studies identified by Medline and other literature searches that met the criteria of being a prospective, randomised clinical trial enrolling over 1000 patients with acute myocardial infarction. The studies...

background contamination of therapeutic recombinant proteins with residual host cell dna must be controlled under the regulatory standards. objectives the current study established a new rapid, sensitive real time polymerase chain reaction (pcr) approach to measure the reliably of the residual escherichia coli (e. coli) host cell genomic dna in the recombinant streptokinase and alfa interferon ...

rt-PA Recombinant tissue plasminogen activator SK Streptokinase UK Urokinase Pro-UK Prourokinase TNK Tenecteplase MCA Middle cerebral artery IU International units ICH Intracerebral hemorrhage PET Positron emission tomography IV Intravenous IA Intra-arterial d: Days Chapter 2 The March of Thrombolytic Therapy for Acute Ischemic Stroke to Clinical Trials: Pre-clinical Thrombolysis and Adjuncts t...

ALI = acute limb ischemia, APSAC = antistreplase, MTD = mechanical thromboembolectomy device, PAT = percutaneous aspiration thromboembolectomy, pro-UK = prourokinase, RPA = reteplase, r-UK = recombinant urokinase, SK = streptokinase, STILE = Surgery versus Thrombolysis for Ischemia of the Lower Extremity [study], tPA = tissue plasminogen activator, TOPAS = Thrombolysis or Peripheral Arterial Su...

Streptokinase is a virulence factor of streptococci and acts as a plasminogen activator to generate the serine protease plasmin which promotes bacterial metastasis. Streptokinase isolated from group C streptococci has been used therapeutically as a thrombolytic agent for many years and its mechanism of action has been extensively studied. However, group A streptococci are associated with invasi...

A computer model was developed to analyze the costs to Medicare and the potential procedure volume associated with alternative strategies for treatment of acute myocardial infarction. The expected cost per case to Medicare for initial hospitalization was approximately $7,200 for conventional treatment, $7,900 for treatment with intravenous streptokinase and $8,400 for treatment with recombinant...